{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:12:57Z","timestamp":1788462777338,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health","award":["R35GM141944"],"award-info":[{"award-number":["R35GM141944"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metabolomics"],"DOI":"10.1007\/s11306-026-02470-0","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:51:15Z","timestamp":1781805075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of metabolite biomarker candidates in detecting HCC in patients with liver cirrhosis"],"prefix":"10.1007","volume":"22","author":[{"given":"Md Mamunur","family":"Rashid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rency S.","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Sajid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaki A.","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habtom W.","family":"Ressom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"2470_CR1","volume":"16","author":"HS Al-Amodi","year":"2024","unstructured":"Al-Amodi, H. S., & Kamel, H. F. (2024). Altered metabolites in hepatocellular carcinoma (HCC) paving the road for metabolomics signature and biomarkers for early diagnosis of HCC. Cureus, 16, Article e71968.","journal-title":"Cureus"},{"key":"2470_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.37796\/2211-8039.1665","volume":"15","author":"GV Bernhardt","year":"2025","unstructured":"Bernhardt, G. V., Bernhardt, K. L., Pinto, J. R. T., & Vashe, A. (2025). Metabolomics in cancer detection: A review of techniques, biomarkers, and clinical utility. Biomedicine (Taipei), 15, 1\u201323.","journal-title":"Biomedicine (Taipei)"},{"key":"2470_CR3","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.4254\/wjh.v14.i9.1730","volume":"14","author":"S Colosimo","year":"2022","unstructured":"Colosimo, S., & Tomlinson, J. W. (2022). Bile acids as drivers and biomarkers of hepatocellular carcinoma. World Journal of Hepatology, 14, 1730\u20131738.","journal-title":"World Journal of Hepatology"},{"key":"2470_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1002\/hep4.2003","volume":"6","author":"Z Farhat","year":"2022","unstructured":"Farhat, Z., Freedman, N. D., Sampson, J. N., Falk, R. T., Koshiol, J., Weinstein, S. J., Albanes, D., Sinha, R., & Loftfield, E. (2022). A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer. Hepatology Communications, 6, 2391\u20132399.","journal-title":"Hepatology Communications"},{"key":"2470_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028510","volume":"101","author":"N Feng","year":"2022","unstructured":"Feng, N., Yu, F., Yu, F., Feng, Y., Zhu, X., Xie, Z., & Zhai, Y. (2022). Metabolomic biomarkers for hepatocellular carcinoma: A systematic review. Medicine (Baltimore), 101, Article e28510.","journal-title":"Medicine (Baltimore)"},{"key":"2470_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087463","volume":"24","author":"B Foglia","year":"2023","unstructured":"Foglia, B., Beltr\u00e0, M., Sutti, S., & Cannito, S. (2023). Metabolic reprogramming of HCC: A new microenvironment for immune responses. International Journal of Molecular Sciences, 24, Article 7463.","journal-title":"International Journal of Molecular Sciences"},{"key":"2470_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s43066-021-00139-y","volume":"11","author":"A Khalil","year":"2021","unstructured":"Khalil, A., Elfert, A., Ghanem, S., Helal, M., Abdelsattar, S., Elgedawy, G., Obada, M., Abdel-Samiee, M., & El-Said, H. (2021). Correction to: The role of metabolomics in hepatocellular carcinoma. Egyptian Liver Journal, 11, 68.","journal-title":"Egyptian Liver Journal"},{"key":"2470_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3350\/cmh.2022.0212","volume":"29","author":"DY Kim","year":"2023","unstructured":"Kim, D. Y., Toan, B. N., Tan, C., Hasan, I., Setiawan, L., Yu, M., Izumi, N., Huyen, N. N., Chow, P. K., Mohamed, R., Chan, S. L., Tanwandee, T., Lee, T., Hai, T. T. N., Yang, T., Lee, W., & Chan, H. L. Y. (2023). Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clin Mol Hepatol, 29, 277\u2013292.","journal-title":"Clin Mol Hepatol"},{"key":"2470_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/hepr.12201","volume":"44","author":"C Li","year":"2014","unstructured":"Li, C., Zhang, Z., Zhang, P., & Liu, J. (2014). Diagnostic accuracy of des-gamma-carboxy prothrombin versus \u03b1-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatology Research, 44, 11.","journal-title":"Hepatology Research"},{"key":"2470_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/1724600818784409","volume":"33","author":"J Li","year":"2018","unstructured":"Li, J., Wang, T., Jin, B., Li, W., Wang, Z., Zhang, H., Song, Y., & Li, N. (2018). Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: A systematic review with meta-analysis. International Journal Of Biological Markers, 33, 353\u2013363.","journal-title":"International Journal Of Biological Markers"},{"key":"2470_CR11","first-page":"4058","volume":"18","author":"N Liu","year":"2019","unstructured":"Liu, N., Feng, J., Lv, Y., Liu, Q., Deng, J., Xia, Y., Guo, C., & Zhou, Y. (2019). Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study. Experimental and Therapeutic Medicine, 18, 4058\u20134066.","journal-title":"Experimental and Therapeutic Medicine"},{"key":"2470_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000525911","volume":"12","author":"H Lu","year":"2022","unstructured":"Lu, H., George, J., Eslam, M., Villanueva, A., Bolondi, L., Reeves, H. L., McCain, M., Chambers, E., Ward, C., Sartika, D., Sands, C., Maslen, L., Lewis, M. R., Ramaswami, R., & Sharma, R. (2022). Discriminatory changes in circulating metabolites as a predictor of hepatocellular cancer in patients with Metabolic (Dysfunction) Associated Fatty Liver Disease. Liver Cancer, 12, 19\u201331.","journal-title":"Liver Cancer"},{"key":"2470_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018). Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice guidance by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.), 68, 723\u2013750.","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"2470_CR14","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.18632\/oncotarget.28306","volume":"13","author":"Y Morine","year":"2022","unstructured":"Morine, Y., Utsunomiya, T., Yamanaka-Okumura, H., Saito, Y., Yamada, S., Ikemoto, T., Imura, S., Kinoshita, S., Hirayama, A., Tanaka, Y., & Shimada, M. (2022). Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis. Oncotarget, 13, 1286\u20131298.","journal-title":"Oncotarget"},{"key":"2470_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13101047","volume":"13","author":"MM Rashid","year":"2023","unstructured":"Rashid, M. M., Varghese, R. S., Ding, Y., & Ressom, H. W. (2023). Biomarker discovery for hepatocellular carcinoma in patients with liver cirrhosis using untargeted metabolomics and lipidomics studies. Metabolites, 13, Article 1047.","journal-title":"Metabolites"},{"key":"2470_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.aca.2012.07.013","volume":"743","author":"HW Ressom","year":"2012","unstructured":"Ressom, H. W., Xiao, J. F., Tuli, L., Varghese, R. S., Zhou, B., Tsai, T. H., Ranjbar, M. R., Zhao, Y., Wang, J., Di Poto, C., Cheema, A. K., Tadesse, M. G., Goldman, R., & Shetty, K. (2012). Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Analytica Chimica Acta, 743, 90\u2013100.","journal-title":"Analytica Chimica Acta"},{"key":"2470_CR17","doi-asserted-by":"publisher","first-page":"101340","DOI":"10.1016\/j.jhepr.2025.101340","volume":"7","author":"K Schulze","year":"2025","unstructured":"Schulze, K., Rose, T. D., Adlung, L., Peschka, M., Pagani, F., Gorgulho, J., Fr\u00fcndt, T. W., Labgaa, I., Haber, P. K., Zimpel, C., Castven, D., Weinmann, A., Garzia-Lezana, T., Waldmann, M., Renn\u00e9, T., Vo\u00df, H., Moritz, M., Orlikowski, D., Schl\u00fcter, H., Baumbach, J., Schwartz, M., Lohse, A. W., Huber, S., Sangro, B., Macias, R. I. R., Izquierdo-Sanchez, L., Banales, J. M., Wege, H., Marquardt, J. U., Villanueva, A., Pauling, J. K., & von Felden, J. (2025). Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis. JHEP Rep, 7, 101340.","journal-title":"JHEP Rep"},{"key":"2470_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112648","volume":"13","author":"CE Thomas","year":"2021","unstructured":"Thomas, C. E., Luu, H. N., Wang, R., Xie, G., Adams-Haduch, J., Jin, A., Koh, W., Jia, W., Behari, J., & Yuan, J. (2021). Association between pre-diagnostic serum bile acids and hepatocellular carcinoma: The Singapore Chinese Health Study. Cancers, 13, Article 2648.","journal-title":"Cancers"},{"key":"2470_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cld.2015.01.005","volume":"19","author":"RJ Wong","year":"2015","unstructured":"Wong, R. J., Ahmed, A., & Gish, R. G. (2015). Elevated alpha-fetoprotein: Differential diagnosis - hepatocellular carcinoma and other disorders. Clinics In Liver Disease, 19, 309\u2013323.","journal-title":"Clinics In Liver Disease"},{"key":"2470_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2147\/OTT.S229835","volume":"13","author":"M Wu","year":"2020","unstructured":"Wu, M., Liu, Z., Li, X., Zhang, A., & Li, N. (2020). Dynamic changes in serum markers and their utility in the early diagnosis of all stages of Hepatitis B-associated hepatocellular carcinoma. OncoTargets and Therapy, 13, 827\u2013840.","journal-title":"OncoTargets and Therapy"},{"key":"2470_CR21","doi-asserted-by":"publisher","first-page":"13120","DOI":"10.1038\/s41598-025-96615-1","volume":"15","author":"Z Zhan","year":"2025","unstructured":"Zhan, Z., Chen, B., Huang, R., Lin, W., Lan, S., Yao, X., Huang, S., Lin, W., Xu, S., Zhou, S., Yu, J., Wang, X., Lin, X., & Guo, Z. (2025). Long-term trends and future projections of liver cancer burden in China from 1990 to 2030. Scientific Reports, 15, 13120\u201313121.","journal-title":"Scientific Reports"},{"key":"2470_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.hepres.2005.12.006","volume":"34","author":"Q Zhang","year":"2006","unstructured":"Zhang, Q., Takahashi, M., Noguchi, Y., Sugimoto, T., Kimura, T., Okumura, A., Ishikawa, T., & Kakumu, S. (2006). Plasma amino acid profiles applied for diagnosis of advanced liver fibrosis in patients with chronic Hepatitis C infection. Hepatology Research, 34, 170\u2013177.","journal-title":"Hepatology Research"},{"key":"2470_CR23","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.3390\/nu16142295","volume":"16","author":"Y Zhu","year":"2024","unstructured":"Zhu, Y., Guo, C., Fan, H., Han, X., Li, Y., Chen, X., & Zhang, T. (2024). Serum branched-chain amino acids and long-term complications of liver cirrhosis: Evidence from a population-based prospective study. Nutrients, 16, 2295.","journal-title":"Nutrients"}],"container-title":["Metabolomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-026-02470-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11306-026-02470-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-026-02470-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:20:10Z","timestamp":1788459610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11306-026-02470-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["2470"],"URL":"https:\/\/doi.org\/10.1007\/s11306-026-02470-0","relation":{},"ISSN":["1573-3890"],"issn-type":[{"value":"1573-3890","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used non-identifiable serum samples collected at MedStar Georgetown University Hospital (IRB 2005\u2009\u2212\u2009206) and Howard University Hospital (IRB 2014-0059), Washington DC. All participating patients provided written informed consent before taking part in the study. Following the participant\u2019s informed consent signature and enrollment, the subject\u2019s blood was drawn, processed, and stored.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"103"}}